Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Oxford Biomedica (LON:OXB) Stock Price

Oxford Biomedica (LON:OXB) had its price objective lifted by equities research analysts at Deutsche Bank Aktiengesellschaft from GBX 735 to GBX 800 in a report released on Friday,Digital Look reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 7.84% from the company’s current price.

Separately, Canaccord Genuity Group reissued a “buy” rating and issued a GBX 451 target price on shares of Oxford Biomedica in a research report on Tuesday, October 7th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of GBX 606.40.

Oxford Biomedica Trading Down 1.2%

OXB traded down GBX 9.13 on Friday, hitting GBX 741.87. The company had a trading volume of 262,724 shares, compared to its average volume of 755,303. The company’s fifty day moving average price is GBX 625.96 and its 200 day moving average price is GBX 544.42. Oxford Biomedica has a 1 year low of GBX 232.50 and a 1 year high of GBX 765. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The firm has a market cap of £895.82 million, a P/E ratio of -20.48 and a beta of 1.09.

Insider Transactions at Oxford Biomedica

In related news, insider Heather Preston acquired 6,175 shares of the firm’s stock in a transaction dated Monday, October 20th. The stock was acquired at an average price of GBX 593 per share, for a total transaction of £36,617.75. 34.83% of the stock is owned by corporate insiders.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.